Andreas Engert M.D. is Professor for Internal Medicine, Hematology and Oncology. He received his medical degree at the University of Hannover and had his medical training at the University of Hannover and the University Hospital of Cologne. Between 1988 and 1990 he worked at the Imperial Cancer Research Fund in London on new immunotherapeutic approaches for cancer. After returning to Cologne, he and his group focused on developing antibody-based immunotherapy for patients with malignant lymphoma resulting in a number of experimental phase I/II clinical trials. He finished his postdoctoral lecture qualification in 1995, was appointed consultant and became head of staff 1996. He was appointed coordinating editor of the Cochrane Hematological Malignancies Group (CHMG) and vice director of the Department for Hematology and Oncology in 2000. After Serving as Secretary of the German Hodgkin Study Group (GHSG) since 1999, Prof. Engert was elected GHSG chairman in 2007. For his scientific work, he has received numerous awards including the Ludwig-Heilmeyer-Medal, the Arthur-Pappenheim Award and the Research Award of the University of Cologne.
The focus of his research for many years has been the development of targeted therapy to combat malignancy. Activities include constructs such as bispecific monoclonal antibodies, radioimmunoconjugates, humanized antibodies or immunoligands for diseases such as neuroblastoma, chronic lymphocytic, acute leukemias and malignant lymphoma. Prof. Engert treats patients with all malignancies and consults for lymphoma patients. In addition he is active in the field of evidence-based medicine as editor of the Cochrane Review Group for Hematological Malignancies (CHMG).
The clinical focus of his work is the German Hodgkin Study Group (GHSG) with all of its different facets including planning and conducting clinical trials of all phases. The GHSG has conducted more than 20 randomized studies with more than 20.000 patients overall registered and is actively involved in a number of early clinical trials evaluating new drugs for patients with Hodgkin Lymphoma.

Evaluates new treatment options for both first-line and relapsed disease

Part I: From Hodgkin's disease to Hodgkin Lymphoma: Epidemiology.- The role of viruses in the genesis of Hodgkin Lymphoma.- Pathology and molecular pathology of Hodgkin Lymphoma.- Microenvironment, cross-talk and immune escape mechanisms.- What will we learn from Genomics and Proteomics in Hodgkin Lymphoma? Part II: Diagnosis and treatment:Clinical evaluation.- Functional imaging.- Prognostic factors.- Principles of radiation techniques in Hodgkin Lymphoma.- Principles of chemotherapy in Hodgkin Lymphoma.- Treatment of early favorable Hodgkin Lymphoma.- Treatment of early unfavorable Hodgkin Lymphoma.- Treatment of advanced-stage Hodgkin Lymphoma.- Relapsed and refractory Hodgkin Lymphoma.- Paediatric Hodgkin Lymphoma. Part III: Special Clinical Situations: Lymphocyte-predominant Hodgkin Lymphoma.- The management of Hodgkin Lymphoma during pregnancy.- The management of HIV-Hodgkin Lymphoma.- The management of elderly patients with Hodgkin Lymphoma.- Allogeneic transplantation for relapsed of Hodgkin Lymphoma.- Targeting CD 30.- Other new agents for patients with Hodgkin Lymphoma. Part IV: Survivorship: Quality of Life in Hodgkin Lymphoma.- Second malignancy risk after treatment of Hodgkin Lymphoma.- Cardiovascular and pulmonary late effects.- Gonadal dysfunction and fertility preservation in Hodgkin Lymphoma patients.

This book examines in detail the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the management appropriate in special clinical circumstances, including in the elderly, pregnant women, and those with lymphocyte-predominant disease. Careful attention is devoted to the emerging individually tailored treatment strategies that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The second edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by the key opinion leaders to reflect recent progress in the field. It will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma.